SSTC3

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

SSTC3  纯度: 98.62%

SSTC3 是 casein 激酶1α (CK1α) 的激动剂(Kd = 32 nM)，可抑制WNT 信号 (EC50 = 30 nM)。SSTC3 与其他类型的 WNT 抑制剂相比，具有极小的胃肠道毒性。

SSTC3

SSTC3 Chemical Structure

CAS No. : 1242422-09-8

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ￥3420 In-stock
5 mg ￥3000 In-stock
10 mg ￥4800 In-stock
50 mg ￥12000 In-stock
100 mg ￥18000 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

SSTC3 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus
  • Cell Cycle/DNA Damage Compound Library
  • Kinase Inhibitor Library
  • Stem Cell Signaling Compound Library
  • Wnt/Hedgehog/Notch Compound Library
  • Anti-Cancer Compound Library
  • Anti-Aging Compound Library
  • Differentiation Inducing Compound Library
  • Cytoskeleton Compound Library
  • Neuroprotective Compound Library
  • Anti-Breast Cancer Compound Library
  • Anti-Liver Cancer Compound Library
  • Anti-Colorectal Cancer Compound Library

生物活性

SSTC3 is a casein kinase 1α (CK1α) activator (Kd = 32 nM) that inhibits WNT signaling (EC50 = 30 nM). SSTC3 exhibits minimal gastrointestinal toxicity compared to other classes of WNT inhibitors[1].

体外研究
(In Vitro)

SSTC3 (0-1μM, 5 days) decreases the viability of HCT116 cells in an on-target manner. This capacity is significantly reduced when the mutant CTNNB1 allele driving its carcinogenic properties is deleted[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line: Colorectal cancer (CRC) cell lines.
Concentration: 0-1 μM.
Incubation Time: 5 days.
Result: Decreased the viability.

Western Blot Analysis[1]

Cell Line: SW403 cells.
Concentration: 100 nM.
Incubation Time: 15 min.
Result: Increased β-catenin phosphate levels.

体内研究
(In Vivo)

SSTC3 can be maintained for 24 hours after treatment[1].
SSTC3 (25 mg/kg, ip once daily for 8-12 days) suppresses the growth of colorectal carcinoma in CD-1 mice[1].
SSTC3 (10 mg/kg, ip once daily for 1 month) inhibits the growth of Apc mutation-driven tumors[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Five-week-old Apcmin mice[1].
Dosage: 10 mg/kg.
Administration: IP for 1 month.
Result: Inhibited the growth of Apc mutation-driven tumors.
Animal Model: CD-1 mice.
Dosage: 25 mg/kg.
Administration: IP once daily for 8-12 days.
Result: Inhibited the growth of HCT116 xenografts.
Attenuated the growth of this metastatic CRC PDX and markedly reduced the cell density of residual cancer.
Reduced the expression of WNT biomarkers in this CRC PDX.

分子量

518.53

Formula

C23H17F3N4O3S2
CAS 号

1242422-09-8
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 125 mg/mL (241.07 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.9285 mL 9.6426 mL 19.2853 mL
5 mM 0.3857 mL 1.9285 mL 3.8571 mL
10 mM 0.1929 mL 0.9643 mL 1.9285 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.08 mg/mL (4.01 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (4.01 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂： 10% DMSO    90% corn oil

    Solubility: ≥ 2.08 mg/mL (4.01 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (4.01 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献

  • [1]. Li B, et al, Differential abundance of CK1α provides selectivity for pharmacological CK1α activators to target WNT-dependent tumors. Sci Signal. 2017 Jun 27;10(485). pii: eaak9916.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务